ENTITY
BeiGene

BeiGene (BGNE US)

131
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
Refresh
14 Sep 2021 04:33

Asia Ex-Japan Positioning:  India & Tech at Record Highs

In this analysis, we provide a detailed overview of investor positioning among 96 active Asia Ex-Japan funds with combined AUM of $80bn.

Logo
167 Views
Share
05 Sep 2021 09:03

China Healthcare Weekly (Sep.3) - Price Reform of Medical Services, Medical Beauty, Functional Food

This article mainly analyzed the pilot plan for the price reform of medical services, new regulation on medical beauty advertisement, functional...

Logo
193 Views
Share
02 Sep 2021 09:02

Jiangsu Hengrui Medicine (600276.CH) - The Concerns and the Outlook

The article analyzed Hengrui in terms of its 2021/1H performance, pipeline, key products, industry policy impact, innovation trend, development...

Logo
267 Views
Share
31 Aug 2021 09:11

Innovent Biologics (1801.HK) - The Strength and the Concerns

This article analyzed Innovent about 2021H1 performance, commercialized products, pipeline, concerns of the Company, and also include thoughts on...

Logo
195 Views
Share
29 Aug 2021 09:10

China Healthcare Weekly (Aug.27)

This article analyzed the logic of China's healthcare sector while its economy is being restructured, two strategies to deal with centralized...

Logo
183 Views
Share
x